Relaxin Receptor 3 Activators
Relaxin Receptor 3 Activators represent a spectrum of chemical compounds designed to indirectly escalate the functional activity of Relaxin Receptor 3 via distinct signal transduction pathways. Forskolin, for instance, catalyzes an upsurge in intracellular cAMP by directly activating adenylate cyclase, which in turn triggers protein kinase A (PKA). The activation of PKA is pivotal in phosphorylating targets within the signaling pathways that Relaxin Receptor 3 operates in, thereby enhancing the receptor's activity. Analogous in function, 8-Bromo-cAMP, a stable cAMP analog, and IBMX, a non-selective inhibitor of phosphodiesterases, both sustain elevated cAMP levels to perpetuate PKA activation. L-Arginine, through its conversion to nitric oxide, and subsequent activation of guanylate cyclase, modulates cGMP levels, which can influence cAMP pathways and thereby potentiate Relaxin Receptor 3 signaling. PDE5 inhibitors such as Sildenafil, Zaprinast, Vardenafil, and Tadalafil, by inhibiting the breakdown of cGMP, indirectly enhance cAMP-mediated pathways, underscoring their role in augmenting Relaxin Receptor 3 activity.
Continuing with this theme, Rolipram and Anagrelide, specific inhibitors of PDE4 and PDE3, respectively, prevent cAMP degradation, reinforcing PKA activity and promoting the signaling pathways associated with Relaxin Receptor 3. The nitric oxide donor Linsidomine amplifies cGMP levels, which can again synergize with cAMP signaling to activate Relaxin Receptor 3. Furthermore, BAY 60-7550, a PDE2 inhibitor, increases both cAMP and cGMP levels, potentially providing a dual amplification of Relaxin Receptor 3's signaling mechanisms. These activators, through their targeted biochemical actions, ensure that Relaxin Receptor 3's involvement in various cellular processes is potentiated, which is achieved by the amplification of cAMP and cGMP signaling pathways rather than direct modulation of the receptor itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, resulting in increased production of cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). PKA phosphorylates various proteins within cells, thereby enhancing the activity of Relaxin Receptor 3 by promoting signaling pathways downstream of cAMP that Relaxin Receptor 3 is associated with. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that resists enzymatic degradation and thus serves as a potent activator of cAMP-dependent pathways. By mimicking cAMP, it activates PKA, which then can lead to the phosphorylation and activation of proteins involved in the signaling cascade of Relaxin Receptor 3. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, or 3-isobutyl-1-methylxanthine, is a non-selective inhibitor of phosphodiesterases (PDEs), leading to increased levels of cAMP within the cell by preventing its degradation. This increased level of cAMP activates PKA which is likely to enhance the signaling pathways that involve Relaxin Receptor 3. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase, which produces nitric oxide (NO), a molecule that can activate guanylate cyclase, increasing levels of cyclic GMP (cGMP). cGMP can modulate cAMP levels and thus indirectly influence signaling pathways that Relaxin Receptor 3 participates in, potentially enhancing its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another PDE5 inhibitor that increases cGMP levels, which may indirectly lead to enhanced signaling through pathways associated with Relaxin Receptor 3, due to cross-talk between cGMP and cAMP signaling. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, an enzyme that degrades cAMP. By preventing cAMP degradation, rolipram can enhance PKA activity and thereby potentially increase the functional activity of Relaxin Receptor 3 through cAMP-dependent pathways. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide is a phosphodiesterase 3 inhibitor, leading to increased cAMP levels and subsequent activation of PKA. Through this mechanism, Anagrelide could enhance the activity of Relaxin Receptor 3 by promoting the signaling pathways that are regulated by cAMP. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, another PDE5 inhibitor, increases cGMP levels in the cell, which can enhance the cAMP signaling pathway. This, in turn, may increase the functional activity of Relaxin Receptor 3 through mechanisms that involve cAMP as a second messenger. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil is a long-acting PDE5 inhibitor that enhances cGMP levels, potentially increasing the activity of cAMP-dependent pathways. This could lead to an indirect enhancement of Relaxin Receptor 3 activity through increased PKA signaling. | ||||||